Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Santhera to discontinue sale of Catena® in Canada
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Small internal jugular veins with restricted outflow are associated with severe multiple sclerosis: a sonographer-blinded, case--control ultrasound study.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.
New approaches in the management of multiple sclerosis.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Fourth PML Case With Tecfidera in MS Calls for Vigilance
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
US court permits generic version of Teva MS drug a year sooner
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

Pages